Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma-Reference-Cited by-同舟云学术

Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma

Published:2012-01-03 Issue:18 Volume:118 Page:4412-4420
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kim Simon P.,Crispen Paul L.,Thompson R. Houston,Weight Christopher J.,Boorjian Stephen A.,Costello Brian A.,Lohse Christine M.,Leibovich Bradley C.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.26695/fullpdf

Reference23 articles.

1. Cancer statistics, 2010;Jemal;CA: Cancer J Clin.,2010

2. The medical treatment of metastatic renal cell cancer;Whelan;EAU Update Ser.,2003

3. Renal cell carcinoma: management of advanced disease;Figlin;J Urol.,1999

4. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome;Zisman;J Urol.,2001

5. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma;Levy;J Urol.,1998

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial;European Urology;2024-09

2. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study;Medicina;2024-07-02

3. Methylation of PCDH17 and NEFH as prognostic biomarker for nonmetastatic RCC: A cohort study;Medicine;2022-07-15

4. Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials;Clinical Genitourinary Cancer;2021-12

5. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study;Clinical Genitourinary Cancer;2021-08